Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caffeine for Hypoxic Ischemic Encephalopathy (CHIME Trial)
NCT06855108Phase 3Recruiting
- Sponsor
- Global Network for Women's and Children's Health Research
- Start
- Apr 2026
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in hypoxic-ischemic encephalopathy (HIE) comparing Caffeine citrate oral solution with Oral placebo (2 arms). Primary endpoint: Composite of all-cause mortality or moderate to severe neurodevelopmental impairment (NDI). Started Apr 2026; status: recruiting.
02
Drugs
caffeine
03
Conditions
hypoxic-ischemic encephalopathy (HIE)
Beyond the preview
Go deeper on NCT06855108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06855108.